Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Drilon

Showing results (91-100 of 268) with videos related to

Pageof 27
Sort By:
Cancer Treatment Reviews|May 11, 2024
NTRK gene fusion testing and management in lung cancerMatteo Repetto, Marina Chiara Garassino, Herbert H Loong, et al.
Frontiers in Oncology|June 5, 2023
Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage Jonathan W Goldman, Lynette M Sholl, Sanja Dacic, et al.
JCO Precision Oncology|February 9, 2022
<i>ALK</i> Fusions in Renal Cell Carcinoma: Response to EntrectinibJessica J Tao, Ge Wei, Roopal Patel, et al.
Cancer Discovery|May 15, 2015
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skippingPaul K Paik, Alexander Drilon, Pang-Dian Fan, et al.
Investigational New Drugs|August 10, 2022
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumorsEmiliano Calvo, Cristiana Sessa, Guilherme Harada, et al.
JCO Precision Oncology|September 6, 2019
Response to Selective RET Inhibition With LOXO-292 in a Patient With <i>RET</i> Fusion-Positive Lung Cancer With Leptomeningeal MetastasesRobin Guo, Mark Schreyer, Jason C Chang, et al.
Cancer Medicine|February 25, 2022
Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatmentDazhi Liu, Michael A Weintraub, Christine Garcia, et al.
Future Oncology (London, England)|August 11, 2022
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive non-small-cell lung cancerMasahiro Tsuboi, Jonathan W Goldman, Yi-Long Wu, et al.
Ophthalmology. Retina|June 8, 2021
Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated RetinopathyJasmine H Francis, Julia Canestraro, Dianna Haggag-Lindgren, et al.
The American Journal of Surgical Pathology|July 19, 2017
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK FusionsJaclyn F Hechtman, Ryma Benayed, David M Hyman, et al.
Pageof 27

Showing results (91-100 of 268) with videos related to

Sort By:
Pageof 27
Cancer Treatment Reviews|May 11, 2024
NTRK gene fusion testing and management in lung cancerMatteo Repetto, Marina Chiara Garassino, Herbert H Loong, et al.
Frontiers in Oncology|June 5, 2023
Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage Jonathan W Goldman, Lynette M Sholl, Sanja Dacic, et al.
JCO Precision Oncology|February 9, 2022
<i>ALK</i> Fusions in Renal Cell Carcinoma: Response to EntrectinibJessica J Tao, Ge Wei, Roopal Patel, et al.
Cancer Discovery|May 15, 2015
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skippingPaul K Paik, Alexander Drilon, Pang-Dian Fan, et al.
Investigational New Drugs|August 10, 2022
Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumorsEmiliano Calvo, Cristiana Sessa, Guilherme Harada, et al.
JCO Precision Oncology|September 6, 2019
Response to Selective RET Inhibition With LOXO-292 in a Patient With <i>RET</i> Fusion-Positive Lung Cancer With Leptomeningeal MetastasesRobin Guo, Mark Schreyer, Jason C Chang, et al.
Cancer Medicine|February 25, 2022
Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatmentDazhi Liu, Michael A Weintraub, Christine Garcia, et al.
Future Oncology (London, England)|August 11, 2022
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive non-small-cell lung cancerMasahiro Tsuboi, Jonathan W Goldman, Yi-Long Wu, et al.
Ophthalmology. Retina|June 8, 2021
Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated RetinopathyJasmine H Francis, Julia Canestraro, Dianna Haggag-Lindgren, et al.
The American Journal of Surgical Pathology|July 19, 2017
Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK FusionsJaclyn F Hechtman, Ryma Benayed, David M Hyman, et al.
Pageof 27